Infographic: we need minimum reporting standards for biologics

Correspondence to Mr. Iain R Murray, Department of Trauma and Orthopaedics, University of Edinburgh, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh EH10 4SA, UK; Iain.Murray@ed.ac.uk Biologic therapies, including platelet rich plasma (PRP) and mesenchymal stem cells, are now widely...

Full description

Saved in:
Bibliographic Details
Published in:British journal of sports medicine 2019-08, Vol.53 (15), p.974-975
Main Authors: Murray, Iain R, Murray, Andrew D, Geeslin, Andrew G, Goudie, Ewan B, White, Timothy O, Petrigliano, Frank A, LaPrade, Robert F
Format: Article
Language:English
Subjects:
Biological products
Joint surgery
Plasma
Quality standards
Report writing
Sports injuries
Stem cells
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Correspondence to Mr. Iain R Murray, Department of Trauma and Orthopaedics, University of Edinburgh, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh EH10 4SA, UK; Iain.Murray@ed.ac.uk Biologic therapies, including platelet rich plasma (PRP) and mesenchymal stem cells, are now widely used to treat a spectrum of sports injuries without robust clinical evidence of efficacy. 1 2 Physicians have a duty to use biologic therapies responsibly, using the best available research evidence to guide treatment decisions for patients. A large number of variables, including processing details, laboratory conditions and formulation composition, influence the effect of biologic therapies. 3-5 Insufficient reporting of these critical variables is widespread, with only 11.5% of clinical studies investigating the use of PRP to manage musculoskeletal conditions, describing the methodology adequately. 6 This precludes interpretation of the nature of biologic formulations delivered, prevents comparison between studies and makes replication by others impossible. The problem is further compounded by a lack of adequate classification systems to enable communication of preparations being used. 7 The use of minimum reporting standards such as CONSORT (Consolidated Standards of Reporting Trials)8 and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)9 have improved the quality of study design.10 While these existing checklists guide the reporting of universal study design features, they do not specify the inclusion of scientific variables that are specific to the study of biologics.
ISSN:0306-3674
1473-0480
DOI:10.1136/bjsports-2017-098122